Comparison/NN
of/IN
the/DT
Genetic/JJ
Alterations/NNS
between/IN
Primary/JJ
Colorectal/JJ
Cancers/NNS
and/CC
Their/PRP$
Corresponding/JJ
Patient-Derived/JJ
Xenograft/NN
Tissues/NNS
./.
====================
Patient-derived/JJ
xenograft/NN
(/(
PDX/NN
)/)
models/NNS
are/VBP
useful/JJ
tools/NNS
for/IN
tumor/NN
biology/NN
research/NN
and/CC
testing/NN
the/DT
efficacy/NN
of/IN
candidate/NN
anticancer/JJ
drugs/NNS
targeting/VBG
the/DT
druggable/JJ
mutations/NNS
identified/VBD
in/IN
tumor/NN
tissue/NN
./.
====================
However/RB
,/,
it/PRP
is/VBZ
still/RB
unknown/JJ
how/WRB
much/RB
of/IN
the/DT
genetic/JJ
alterations/NNS
identified/VBD
in/IN
primary/JJ
tumors/NNS
are/VBP
consistently/RB
detected/VBN
in/IN
tumor/NN
tissues/NNS
in/IN
the/DT
PDX/NN
model/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
analyzed/VBD
the/DT
genetic/JJ
alterations/NNS
of/IN
three/CD
primary/JJ
colorectal/JJ
cancers/NNS
(/(
CRCs/NNS
)/)
and/CC
matched/VBN
xenograft/NN
tissues/NNS
in/IN
PDX/NN
models/NNS
using/VBG
a/DT
next-generation/JJ
sequencing/NN
cancer/NN
panel/NN
./.
====================
Of/IN
the/DT
17/CD
somatic/JJ
mutations/NNS
identified/VBD
from/IN
the/DT
three/CD
CRCs/NNS
,/,
14/CD
(/(
82.4/CD
%/NN
)/)
were/VBD
consistently/RB
identified/VBN
in/IN
both/DT
primary/JJ
and/CC
xenograft/NN
tumors/NNS
./.
====================
The/DT
other/JJ
three/CD
mutations/NNS
identified/VBD
in/IN
the/DT
primary/JJ
tumor/NN
were/VBD
not/RB
detected/VBN
in/IN
the/DT
xenograft/NN
tumor/NN
tissue/NN
./.
====================
There/EX
was/VBD
no/DT
newly/RB
identified/VBN
mutation/NN
in/IN
the/DT
xenograft/NN
tumor/NN
tissues/NNS
./.
====================
In/IN
addition/NN
to/TO
the/DT
somatic/JJ
mutations/NNS
,/,
the/DT
copy/NN
number/NN
alteration/NN
profiles/NNS
were/VBD
also/RB
largely/RB
consistent/JJ
between/IN
the/DT
primary/JJ
tumor/NN
and/CC
xenograft/NN
tissue/NN
./.
====================
All/DT
of/IN
these/DT
data/NNS
suggest/VBP
that/IN
the/DT
PDX/NN
tumor/NN
model/NN
preserves/VBZ
the/DT
majority/NN
of/IN
the/DT
key/JJ
mutations/NNS
detected/VBN
in/IN
the/DT
primary/JJ
tumor/NN
site/NN
./.
====================
This/DT
study/NN
provides/VBZ
evidence/NN
that/IN
the/DT
PDX/NN
model/NN
is/VBZ
useful/JJ
for/IN
testing/VBG
targeted/VBN
therapies/NNS
in/IN
the/DT
clinical/JJ
field/NN
and/CC
research/NN
on/IN
precision/NN
medicine/NN
./.
====================
The/DT
recent/JJ
advent/JJ
of/IN
next-generation/NN
sequencing/NN
(/(
NGS/NN
)/)
technologies/NNS
has/VBZ
accelerated/VBN
the/DT
realization/NN
of/IN
precision/NN
medicine/NN
,/,
especially/RB
for/IN
cancer/NN
treatment/NN
[/(
1/CD
]/)
./.
====================
With/IN
NGS/NN
tools/NNS
,/,
the/DT
mutation-based/VBN
determination/NN
of/IN
an/DT
actionable/JJ
drug/NN
is/VBZ
possible/JJ
,/,
and/CC
side/JJ
effects/NNS
of/IN
a/DT
drug/NN
can/MD
be/VB
minimized/VBN
[/(
2/CD
,/,
3/CD
]/)
./.
====================
Another/DT
technical/JJ
revolution/NN
for/IN
precision/NN
medicine/NN
is/VBZ
the/DT
development/NN
of/IN
the/DT
patient-derived/JJ
xenograft/NN
(/(
PDX/NN
)/)
model/NN
./.
====================
The/DT
basic/JJ
principle/JJ
of/IN
the/DT
PDX/NN
model/NN
is/VBZ
to/TO
engraft/VB
human/JJ
tumor/NN
tissues/NNS
or/CC
cells/NNS
onto/IN
immuno-deficient/JJ
mice/NNS
and/CC
expand/CC
the/DT
tumor/NN
tissues/NNS
in/IN
the/DT
immuno-deficient/JJ
mouse/NN
to/TO
test/VB
the/DT
efficacy/NN
of/IN
candidate/NN
anti-cancer/JJ
drugs/NNS
[/(
4/CD
,/,
5/CD
]/)
./.
====================
Once/RB
a/DT
druggable/JJ
mutation/NN
is/VBZ
identified/VBN
by/IN
NGS/NN
,/,
the/DT
PDX/NN
model/NN
that/DT
has/VBZ
been/VBN
established/VBN
from/IN
the/DT
same/JJ
patient/NN
can/MD
provide/VB
an/DT
efficient/JJ
way/NN
to/TO
validate/VB
the/DT
candidate/NN
target/NN
therapy/NN
./.
====================
Even/RB
though/IN
an/DT
in/FW
vitro/FW
culture/NN
of/IN
the/DT
primary/JJ
tumor/NN
cell/NN
can/MD
also/RB
be/VB
applicable/JJ
for/IN
drug/NN
efficacy/NN
screening/NN
,/,
the/DT
PDX/NN
mouse/NN
model/NN
has/VBZ
advantages/NNS
compared/VBN
with/IN
in/FW
vitro/FW
tissue/NN
cultures/NNS
./.
====================
For/IN
example/NN
,/,
under/IN
artificial/JJ
in/IN
vitro/FW
culture/NN
conditions/NNS
,/,
cancer/NN
cells/NNS
may/MD
acquire/VB
further/RBR
genomic/JJ
alterations/NNS
and/CC
phenotypic/JJ
changes/NNS
to/TO
survive/VB
,/,
whereas/IN
PDX/NN
models/NNS
appear/VBP
to/TO
have/VB
greater/JJR
similarity/NN
to/TO
primary/JJ
tumors/NNS
[/(
6/CD
,/,
7/CD
]/)
./.
====================
Indeed/RB
,/,
according/VBG
to/TO
Gu/NN
et/FW
al/JJ
./.
====================
[/(
8/CD
]/)
,/,
PDX-based/JJ
mouse/NN
trials/NNS
have/VBP
shown/VBN
similar/JJ
results/NNS
as/IN
cancer/NN
patient-based/VBN
clinical/JJ
trials/NNS
./.
====================
According/VBG
to/TO
Fichtner/NN
et/FW
al/JJ
./.
====================
[/(
9/CD
]/)
,/,
most/JJS
of/IN
the/DT
key/JJ
genetic/JJ
alterations/NNS
identified/VBD
in/IN
primary/JJ
tumors/NNS
were/VBD
consistently/RB
detected/VBN
in/IN
the/DT
PDX/NN
models/NNS
,/,
and/CC
the/DT
PDX/NN
models/NNS
had/VBD
similar/JJ
outcomes/NNS
as/IN
chemotherapy/NN
./.
====================
However/RB
,/,
it/PRP
is/VBZ
still/RB
unknown/JJ
how/WRB
many/JJ
of/IN
the/DT
genetic/JJ
alterations/NNS
identified/VBD
in/IN
primary/JJ
tumors/NNS
are/VBP
consistently/RB
detected/VBN
in/IN
tumor/NN
tissues/NNS
in/IN
the/DT
PDX/NN
model/NN
that/DT
has/VBZ
been/VBN
established/VBN
from/IN
the/DT
same/JJ
patient/NN
./.
====================
Especially/RB
,/,
the/DT
consistency/NN
of/IN
key/JJ
genetic/JJ
alterations/NNS
between/IN
primary/JJ
tumors/NNS
and/CC
the/DT
PDX/NN
model/NN
is/VBZ
very/RB
important/JJ
to/TO
test/VB
the/DT
efficacy/NN
of/IN
candidate/NN
anti-cancer/JJ
drugs/NNS
that/WDT
have/VBP
been/VBN
designed/VBN
,/,
based/VBN
on/IN
the/DT
mutation/NN
profiles/NNS
in/IN
the/DT
primary/JJ
tumor/NN
./.
====================
To/TO
address/VB
this/DT
issue/NN
,/,
we/PRP
analyzed/VBD
the/DT
mutations/NNS
of/IN
three/CD
primary/JJ
colorectal/JJ
cancers/NNS
(/(
CRCs/NNS
)/)
and/CC
matched/VBN
xenograft/NN
tissues/NNS
in/IN
PDX/NN
models/NNS
by/IN
NGS-based/JJ
cancer/NN
panel/NN
analysis/NN
./.
====================
Then/RB
,/,
we/PRP
compared/VBD
the/DT
mutational/JJ
status/NN
between/IN
the/DT
primary/JJ
tumors/NNS
and/CC
PDX/NN
models/NNS
./.
====================
Primary/JJ
and/CC
matched/VBN
PDX/NN
tumor/NN
samples/NNS
====================
CRC/NN
tissues/NNS
and/CC
matched/VBN
normal/JJ
samples/NNS
were/VBD
collected/VBN
from/IN
three/CD
CRC/NN
patients/NNS
at/IN
Seoul/JJ
St./FW
Mary/JJ
’/CD
s/NNS
Hospital/JJ
(/(
Seoul/JJ
,/,
Korea/NN
)/)
with/IN
the/DT
approval/JJ
of/IN
the/DT
institutional/JJ
review/NN
board/IN
./.
====================
Corresponding/VBG
PDX/NN
tissues/NNS
of/IN
the/DT
xenograft/NN
mouse/NN
models/NNS
from/IN
the/DT
same/JJ
cases/NNS
were/VBD
obtained/VBN
with/IN
the/DT
approval/JJ
of/IN
the/DT
Institutional/JJ
Animal/JJ
Care/NN
and/CC
Use/NN
Committee/NN
(/(
IACUC/NN
)/)
of/IN
Catholic/JJ
University/NN
of/IN
Korea/NN
(/(
Seoul/JJ
,/,
Korea/NN
)/)
./.
====================
General/JJ
information/NN
on/IN
the/DT
three/CD
CRC/NN
cases/NNS
(/(
normal/JJ
,/,
primary/JJ
tumor/NN
,/,
and/CC
PDX/NN
tissue/NN
sets/NNS
)/)
is/VBZ
available/JJ
in/IN
Supplementary/JJ
Table/JJ
1/CD
./.
====================
Primary/JJ
tumor/NN
samples/NNS
were/VBD
cut/JJ
and/CC
stained/VBD
with/IN
hematoxylin/NN
and/CC
eosin/NN
(/(
H/NN
&/CC
E/NN
)/)
./.
====================
The/DT
H/NN
&/CC
E-stained/JJ
slides/NNS
were/VBD
reviewed/VBN
by/IN
a/DT
pathologist/NN
to/TO
mark/VB
tumor/NN
cell-rich/JJ
areas/NNS
and/CC
used/VBN
as/IN
a/DT
guide/NN
for/IN
the/DT
microdissections/NNS
./.
====================
DNA/NN
was/VBD
extracted/VBN
from/IN
the/DT
microdissected/VBN
tissue/NN
and/CC
matched/VBN
blood/NN
using/VBG
the/DT
DNeasy/NN
Blood/NN
and/CC
Tissue/NN
Kit/NN
(/(
Qiagen/NN
,/,
Hilden/JJ
,/,
Germany/NNP
)/)
./.
====================
The/DT
DNA/NN
was/VBD
quantified/VBN
with/IN
the/DT
Qubit/NN
dsDNA/JJ
HS/NN
assay/NN
kit/NN
on/IN
a/DT
Qubit/NN
fluorometer/NN
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
,/,
Waltham/NN
,/,
MA/NN
,/,
USA/NN
)/)
./.
====================
Library/JJ
preparation/NN
and/CC
Ion/NN
S5/NN
sequencing/NN
====================
We/PRP
used/VBD
a/DT
custom/JJ
NGS/NN
panel/NN
,/,
OncoChase-AS01/NN
(/(
ConnectaGen/NN
,/,
Seoul/JJ
,/,
Korea/NN
)/)
,/,
targeting/VBG
95/CD
cancer-related/VBD
genes/NNS
(/(
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
[/(
10/CD
]/)
./.
====================
Ten/CD
nanograms/NNS
of/IN
DNA/NN
was/VBD
amplified/VBN
,/,
digested/JJ
,/,
and/CC
barcoded/JJ
using/VBG
the/DT
Ion/NN
Ampliseq/NN
Library/JJ
kit/NN
2.0/CD
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
)/)
and/CC
Ion/NN
Xpress/NN
barcode/IN
adapter/NN
kit/NN
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
)/)
according/VBG
to/TO
the/DT
manufacturer/NN
’/CD
s/NNS
instructions/NNS
./.
====================
The/DT
amplified/VBN
libraries/NNS
were/VBD
quantified/VBN
using/VBG
a/DT
Qubit/NN
fluorometer/NN
,/,
the/DT
Qubit/NN
dsDNA/JJ
HS/NN
assay/NN
kit/NN
,/,
and/CC
the/DT
Ion/NN
Library/JJ
TaqMan/NN
Quantitation/NN
kit/NN
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
)/)
./.
====================
The/DT
libraries/NNS
were/VBD
then/RB
templated/VBN
on/IN
an/DT
Ion/NN
Chef/NNP
System/NN
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
)/)
using/VBG
Ion/JJ
520/CD
and/CC
Ion/NN
530/CD
Chef/NNP
Reagents/NNS
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
)/)
according/VBG
to/TO
the/DT
manufacturer/NN
’/CD
s/NNS
instructions/NNS
./.
====================
The/DT
prepared/VBN
libraries/NNS
were/VBD
sequenced/VBN
on/IN
an/DT
Ion/NN
S5/NN
Sequencer/NN
using/VBG
an/DT
Ion/NN
530/CD
chip/NN
and/CC
Ion/NN
S5/NN
Sequencing/NN
Reagents/NNS
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
)/)
./.
====================
Data/NNS
analysis/NN
====================
Using/VBG
the/DT
Ion/NN
Torrent/JJ
Suite/JJ
v5.2.2/CD
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
)/)
for/IN
Ion/NN
S5/NN
,/,
we/PRP
analyzed/VBD
raw/RB
data/NNS
and/CC
performed/VBN
alignment/RB
of/IN
the/DT
sequencing/NN
reads/VBZ
to/TO
the/DT
reference/NN
genome/NN
(/(
Human/JJ
Genome/NN
build/JJ
19/CD
)/)
./.
====================
The/DT
coverage/JJ
analysis/NN
was/VBD
performed/VBN
using/VBG
the/DT
Ion/NN
Torrent/JJ
Coverage/NN
analysis/NN
plug-in/CC
software/JJ
v5.2.1.2/CD
,/,
and/CC
variants/NNS
were/VBD
detected/VBN
using/VBG
the/DT
Variant/JJ
Caller/NN
plug-in/JJ
v5.2.2.41/NN
with/IN
low-stringency/NN
settings/NNS
./.
====================
We/PRP
also/RB
used/VBN
ANNOVAR/NN
,/,
which/WDT
is/VBZ
a/DT
tool/NN
that/DT
annotates/VBZ
called/VBN
variants/NNS
,/,
querying/VBG
a/DT
knowledge/NN
database/NN
with/IN
various/JJ
clinical/JJ
information/NN
./.
====================
We/PRP
used/VBD
in-out/IN
pipelines/NNS
to/TO
filter/JJR
mouse/NN
contamination/NN
,/,
with/IN
reference/NN
to/TO
a/DT
database/NN
of/IN
SNPs/NNS
and/CC
another/DT
study/NN
[/(
11/CD
]/)
./.
====================
The/DT
variant/JJ
calls/NNS
were/VBD
examined/VBN
manually/RB
with/IN
the/DT
Integrative/JJ
Genomics/NNS
Viewer/JJR
(/(
IGV/NN
)/)
from/IN
the/DT
Broad/JJ
Institute/JJ
[/(
12/CD
,/,
13/CD
]/)
,/,
and/CC
we/PRP
identified/VBD
somatic/JJ
mutations/NNS
using/VBG
the/DT
COSMIC/NN
database/NN
and/CC
The/DT
Cancer/NN
Genome/NN
Atlas/IN
(/(
TCGA/NN
)/)
database/NN
./.
====================
The/DT
mutations/NNS
were/VBD
filtered/VBN
with/IN
matched/VBN
normal/JJ
data/NNS
to/TO
reduce/VB
false/VBP
positives/VBZ
./.
====================
To/TO
define/VB
copy/NN
number/NN
alterations/NNS
(/(
CNAs/NNS
)/)
,/,
we/PRP
used/VBD
NEXUS/NN
software/JJ
9.0/CD
(/(
Biodiscovery/NNP
,/,
El/NNP
Segundo/NN
,/,
CA/NNP
,/,
USA/NN
)/)
[/(
1/CD
,/,
14/CD
]/)
./.
====================
Sanger/NN
sequencing/NN
====================
We/PRP
conducted/VBD
PCR/NN
amplification/NN
and/CC
Sanger/NN
sequencing/NN
to/TO
validate/VB
single-nucleotide/JJ
variants/NNS
and/CC
deletions/NNS
./.
====================
We/PRP
selected/VBD
exon/NN
15/CD
of/IN
CDH1/NN
,/,
exon/NN
12/CD
of/IN
ERBB2/NN
,/,
and/CC
exon/NN
8/CD
of/IN
ESR1/NN
./.
====================
The/DT
primers/NNS
that/DT
were/VBD
used/VBN
for/IN
the/DT
Sanger/NN
validation/NN
are/VBP
available/JJ
in/IN
Supplementary/JJ
Table/JJ
2/CD
./.
====================
Histological/JJ
features/NNS
of/IN
primary/JJ
and/CC
PDX/NN
tumors/NNS
====================
All/DT
of/IN
the/DT
PDX/NN
tumors/NNS
used/VBN
in/IN
this/DT
study/NN
were/VBD
passage-three/JJ
tissues/NNS
./.
====================
The/DT
three/CD
primary/JJ
tumors/NNS
showed/VBD
adenocarcinomas/NNS
of/IN
the/DT
colon/NN
,/,
and/CC
the/DT
histological/JJ
features/NNS
of/IN
the/DT
tumor/NN
tissues/NNS
of/IN
the/DT
PDX/NN
models/NNS
from/IN
the/DT
same/JJ
CRC/NN
patients/NNS
were/VBD
identical/JJ
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
The/DT
tumor/NN
cell/NN
purity/NN
of/IN
the/DT
primary/JJ
tumor/NN
tissues/NNS
and/CC
xenograft/NN
tumor/NN
tissues/NNS
was/VBD
comparable/JJ
,/,
but/CC
the/DT
xenografts/NNS
showed/VBD
slightly/RB
higher/JJR
purity/NN
than/IN
primary/JJ
CRCs/NNS
(/(
all/DT
>/JJR
60/CD
%/NN
)/)
./.
====================
Targeted/VBN
deep/NN
sequencing/NN
====================
We/PRP
performed/VBD
targeted/VBN
NGS/NN
,/,
covering/VBG
95/CD
cancer-related/VBD
genes/NNS
,/,
for/IN
specimens/NNS
of/IN
the/DT
three/CD
primary/JJ
CRCs/NNS
and/CC
corresponding/JJ
PDX/NN
tumors/NNS
./.
====================
DNA/NN
from/IN
the/DT
blood/NN
of/IN
the/DT
three/CD
patients/NNS
was/VBD
also/RB
sequenced/VBN
to/TO
determine/VB
the/DT
somatic/JJ
alterations/NNS
./.
====================
The/DT
average/JJ
coverage/NN
of/IN
the/DT
sequencing/NN
depth/NN
was/VBD
958×/CD
(/(
range/NN
,/,
834.4/CD
to/TO
1017×/CD
)/)
(/(
Supplementary/JJ
Table/JJ
3/CD
)/)
./.
====================
Through/IN
the/DT
filtering/JJ
steps/NNS
,/,
we/PRP
identified/VBD
17/CD
non-silent/JJ
somatic/JJ
mutations/NNS
across/IN
13/CD
cancer-related/JJ
genes/NNS
(/(
ALK/NN
,/,
APC/NN
,/,
BRAF/NN
,/,
CDH1/NN
,/,
CDKN2A/NN
,/,
ERBB2/NN
,/,
ESR1/NN
,/,
FBXW7/NN
,/,
GNA11/NN
,/,
RAF1/NN
,/,
RB1/NN
,/,
SF3B1/NN
,/,
and/CC
TP53/NN
)/)
(/(
Table/JJ
1/CD
)/)
./.
====================
Among/IN
them/PRP
,/,
three/CD
mutations/NNS
(/(
APC/NN
,/,
TP53/NN
,/,
and/CC
FBXW7/NN
)/)
overlapped/VBD
with/IN
the/DT
TCGA/NN
projects/NNS
and/CC
the/DT
top/NN
20/CD
colon/NN
and/CC
rectal/JJ
adenocarcinoma/NN
genes/NNS
in/IN
the/DT
COSMIC/NN
database/NN
(/(
http/NN
:/:
//cancer.sanger.ac.uk/cosmic/JJ
)/)
./.
====================
Comparison/NN
of/IN
genetic/JJ
alteration/NN
profiles/NNS
between/IN
primary/JJ
and/CC
PDX/NN
tumors/NNS
====================
Next/RB
,/,
we/PRP
examined/VBD
how/WRB
consistent/JJ
the/DT
somatic/JJ
mutations/NNS
identified/VBD
in/IN
the/DT
primary/JJ
CRC/NN
tissues/NNS
and/CC
corresponding/JJ
tumor/NN
tissues/NNS
from/IN
the/DT
PDX/NN
mouse/NN
models/NNS
were/VBD
./.
====================
Of/IN
the/DT
17/CD
somatic/JJ
mutations/NNS
,/,
14/CD
were/VBD
consistently/RB
identified/VBN
in/IN
both/CC
primary/JJ
and/CC
xenograft/NN
tumors/NNS
(/(
Fig/NN
./.
====================
2A/NN
)/)
./.
====================
However/RB
,/,
3/CD
mutations/NNS
that/WDT
were/VBD
identified/VBN
in/IN
the/DT
primary/JJ
tumor/NN
were/VBD
not/RB
detected/VBN
in/IN
the/DT
xenograft/NN
tumor/NN
tissue/NN
(/(
Fig/NN
./.
====================
2A/NN
)/)
./.
====================
Overall/RB
,/,
variant/JJ
allele/NN
frequencies/NNS
(/(
VAFs/NNS
)/)
in/IN
the/DT
xenografts/NNS
were/VBD
higher/JJR
than/IN
in/IN
the/DT
primary/JJ
CRCs/NNS
(/(
Fig/NN
./.
====================
2B/NN
)/)
./.
====================
There/EX
was/VBD
no/DT
newly/RB
identified/VBN
mutation/NN
in/IN
the/DT
xenograft/NN
tumor/NN
tissues/NNS
./.
====================
In/IN
the/DT
CCA-1/NN
case/NN
,/,
five/CD
mutations/NNS
(/(
ALK/NN
,/,
APC/NN
,/,
FBWX7/NN
,/,
RB1/NN
,/,
and/CC
TP53/NN
)/)
that/WDT
were/VBD
identified/VBN
in/IN
the/DT
primary/JJ
tumor/NN
were/VBD
consistently/RB
detected/VBN
in/IN
the/DT
xenograft/NN
tumor/NN
./.
====================
The/DT
average/JJ
VAF/NN
in/IN
the/DT
primary/JJ
tumor/NN
and/CC
xenograft/NN
was/VBD
36.2/CD
%/NN
±/CD
15.7/CD
%/NN
and/CC
58.6/CD
%/NN
±/CD
29.6/CD
%/NN
,/,
respectively/RB
./.
====================
In/IN
the/DT
CCA-2/NN
case/NN
,/,
two/CD
mutations/NNS
(/(
APC/NN
and/CC
BRAF/NN
)/)
in/IN
the/DT
primary/JJ
tumor/NN
were/VBD
consistently/RB
detected/VBN
in/IN
the/DT
xenograft/NN
tumor/NN
./.
====================
In/IN
this/DT
case/NN
,/,
two/CD
independent/JJ
mutations/NNS
were/VBD
detected/VBN
in/IN
the/DT
APC/NN
gene/NN
(/(
Table/JJ
1/CD
)/)
,/,
and/CC
both/CC
of/IN
them/PRP
were/VBD
consistently/RB
detected/VBN
in/IN
the/DT
primary/JJ
and/CC
xenograft/NN
tumors/NNS
./.
====================
The/DT
average/JJ
VAF/NN
(/(
%/NN
)/)
in/IN
the/DT
primary/JJ
tumor/NN
and/CC
xenograft/NN
was/VBD
25.7/CD
%/NN
±/CD
0.8/CD
%/NN
and/CC
45.8/CD
%/NN
±/CD
1.6/CD
%/NN
,/,
respectively/RB
./.
====================
In/IN
the/DT
CCA-3/NN
case/NN
,/,
nine/CD
mutations/NNS
were/VBD
identified/VBN
in/IN
the/DT
primary/JJ
tumor/NN
,/,
and/CC
six/CD
of/IN
them/PRP
(/(
BRAF/NN
,/,
CDKN2A/NN
,/,
GNA11/NN
,/,
RAF1/NN
,/,
SF3B1/NN
,/,
and/CC
TP53/NN
)/)
were/VBD
consistently/RB
detected/VBN
in/IN
the/DT
corresponding/JJ
xenograft/NN
tissue/NN
;/:
however/RB
,/,
the/DT
other/JJ
three/CD
mutations/NNS
(/(
CDH1/NN
,/,
ERBB2/NN
,/,
and/CC
ESR1/NN
)/)
were/VBD
not/RB
detected/VBN
in/IN
the/DT
xenograft/NN
./.
====================
The/DT
read/JJ
depths/NNS
in/IN
the/DT
three/CD
genes/NNS
in/IN
the/DT
PDX/NN
tissue/NN
were/VBD
1,694×/CD
,/,
519×/CD
,/,
and/CC
613×/CD
,/,
respectively/RB
,/,
which/WDT
is/VBZ
similar/JJ
to/TO
the/DT
average/NN
read/VBN
depth/NN
./.
====================
This/DT
result/NN
suggests/VBZ
that/IN
the/DT
inconsistency/NN
of/IN
the/DT
three/CD
mutations/NNS
between/IN
primary/JJ
tumors/NNS
and/CC
PDX/NN
models/NNS
night/CD
not/RB
be/VB
due/JJ
to/TO
the/DT
relatively/RB
shallow/JJ
read/VBN
./.
====================
To/TO
further/RBR
verify/RB
whether/IN
the/DT
inconsistent/JJ
result/NN
was/VBD
a/DT
real/JJ
difference/NN
or/CC
due/JJ
to/TO
technical/JJ
errors/NNS
,/,
we/PRP
performed/VBD
Sanger/NN
sequencing/NN
for/IN
the/DT
three/CD
genes/NNS
and/CC
confirmed/VBD
that/IN
the/DT
mutations/NNS
of/IN
the/DT
three/CD
genes/NNS
existed/VBD
only/RB
in/IN
the/DT
primary/JJ
tumor/NN
(/(
Supplementary/JJ
Fig/NN
./.
====================
2/CD
)/)
./.
====================
We/PRP
also/RB
examined/VBN
how/WRB
consistent/JJ
the/DT
CNAs/NNS
that/DT
were/VBD
identified/VBN
in/IN
the/DT
primary/JJ
CRC/NN
tissues/NNS
and/CC
the/DT
corresponding/JJ
tumor/NN
tissues/NNS
from/IN
the/DT
PDX/NN
mouse/NN
models/NNS
were/VBD
./.
====================
The/DT
CNA/NN
profiles/NNS
in/IN
the/DT
primary/JJ
tumors/NNS
were/VBD
largely/RB
consistent/JJ
with/IN
those/DT
in/IN
the/DT
xenograft/NN
tumors/NNS
(/(
Table/JJ
2/CD
)/)
./.
====================
Fig/NN
./.
====================
3/CD
illustrates/VBZ
an/DT
example/NN
of/IN
CNA/NN
profiles/NNS
that/IN
were/VBD
identified/VBN
in/IN
primary/JJ
and/CC
xenograft/NN
tumors/NNS
(/(
CCA-1/NN
)/)
,/,
harboring/VBG
amplifications/NNS
of/IN
RAF1/NN
(/(
chromosome/NN
3p/NN
)/)
,/,
FGFR1/NN
(/(
chromosome/NN
8p/NN
)/)
,/,
and/CC
MYC/NN
(/(
chromosome/NN
8q/NN
)/)
./.
====================
The/DT
CNA/NN
profiles/NNS
of/IN
the/DT
other/JJ
two/CD
CRCs/NNS
are/VBP
available/JJ
in/IN
Supplementary/JJ
Fig/NN
./.
====================
3/CD
./.
====================
In/IN
principle/JJ
,/,
xenografts/NNS
of/IN
human/JJ
tumor/NN
tissue/NN
onto/IN
mice/NNS
would/MD
be/VB
an/DT
ideal/JJ
tool/NN
for/IN
testing/VBG
the/DT
response/NN
in/IN
vivo/FW
to/TO
anticancer/JJ
drugs/NNS
for/IN
individual/JJ
patients/NNS
,/,
because/IN
PDX/NN
models/NNS
preserve/VBP
the/DT
main/JJ
characteristics/NNS
of/IN
the/DT
original/JJ
tumor/NN
,/,
such/JJ
as/IN
mutation/NN
profile/NN
and/CC
morphology/NN
[/(
15/CD
]/)
./.
====================
However/RB
,/,
it/PRP
is/VBZ
unclear/JJ
whether/IN
the/DT
characteristics/NNS
of/IN
the/DT
mutations/NNS
in/IN
the/DT
primary/JJ
tumor/NN
are/VBP
well/RB
preserved/VBN
in/IN
the/DT
mouse/NN
xenograft/NN
or/CC
not/RB
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
aimed/VBD
to/TO
check/VB
whether/IN
the/DT
genetic/JJ
alterations/NNS
that/IN
are/VBP
identified/VBN
in/IN
primary/JJ
tumors/NNS
are/VBP
consistent/JJ
with/IN
the/DT
corresponding/JJ
PDX/NN
xenograft/NN
tumors/NNS
using/VBG
CRC/NN
PDX/NN
models/NNS
./.
====================
For/IN
this/DT
,/,
we/PRP
compared/VBD
the/DT
genetic/JJ
alteration/NN
profiles/NNS
for/IN
three/CD
pairs/NNS
of/IN
primary/JJ
CRCs/NNS
and/CC
their/PRP$
corresponding/JJ
PDX/NN
tumors/NNS
./.
====================
To/TO
rule/VB
out/RP
the/DT
passage/NN
effect/NN
of/IN
mutation/NN
profiles/NNS
in/IN
the/DT
PDX/NN
model/NN
,/,
we/PRP
used/VBD
passage-three/JJ
samples/NNS
for/IN
all/DT
three/CD
CRCs/NNS
./.
====================
Through/IN
this/DT
analysis/NN
,/,
we/PRP
observed/VBD
that/IN
most/JJS
of/IN
the/DT
key/JJ
somatic/JJ
mutations/NNS
(/(
14/17/CD
)/)
were/VBD
preserved/VBN
in/IN
the/DT
xenograft/NN
./.
====================
In/IN
terms/NNS
of/IN
the/DT
consistency/NN
of/IN
the/DT
somatic/JJ
mutations/NNS
,/,
two/CD
of/IN
the/DT
three/CD
CRC/NN
cases/NNS
showed/VBD
perfectly/RB
consistent/JJ
mutation/NN
profiles/NNS
between/IN
the/DT
primary/JJ
tumor/NN
and/CC
xenograft/NN
,/,
and/CC
the/DT
other/JJ
case/NN
showed/VBD
a/DT
partly/RB
consistent/JJ
profile/NN
./.
====================
Overall/RB
,/,
14/CD
of/IN
the/DT
17/CD
(/(
82.4/CD
%/NN
)/)
somatic/JJ
mutations/NNS
that/WDT
were/VBD
identified/VBN
in/IN
the/DT
three/CD
CRCs/NNS
were/VBD
consistent/JJ
between/IN
the/DT
primary/JJ
tumor/NN
and/CC
xenograft/NN
./.
====================
This/DT
result/NN
is/VBZ
largely/RB
consistent/JJ
with/IN
previous/JJ
observations/NNS
in/IN
diverse/JJ
cancers/NNS
[/(
16/CD
,/,
17/CD
]/)
./.
====================
In/IN
addition/NN
to/TO
the/DT
somatic/JJ
mutations/NNS
,/,
the/DT
CNA/NN
profiles/NNS
were/VBD
also/RB
largely/RB
consistent/JJ
between/IN
the/DT
primary/JJ
tumor/NN
and/CC
xenograft/NN
./.
====================
All/DT
of/IN
these/DT
data/NNS
suggest/VBP
that/IN
the/DT
PDX/NN
tumor/NN
model/NN
preserves/VBZ
the/DT
majority/NN
of/IN
key/JJ
mutations/NNS
that/WDT
are/VBP
detected/VBN
in/IN
the/DT
primary/JJ
tumor/NN
site/NN
./.
====================
This/DT
study/NN
provides/VBZ
evidence/NN
that/IN
the/DT
PDX/NN
model/NN
is/VBZ
useful/JJ
for/IN
testing/VBG
target/NN
therapies/NNS
in/IN
the/DT
clinical/JJ
field/NN
and/CC
research/NN
on/IN
precision/NN
medicine/NN
./.
====================
There/EX
are/VBP
several/JJ
limitations/NNS
in/IN
this/DT
study/NN
./.
====================
First/RB
,/,
the/DT
number/NN
of/IN
cases/NNS
might/MD
not/RB
have/VB
been/VBN
enough/IN
to/TO
conclude/VB
the/DT
consistency/NN
of/IN
key/JJ
genetic/JJ
mutations/NNS
between/IN
the/DT
primary/JJ
tumor/NN
and/CC
xenograft/NN
objectively/RB
./.
====================
Second/RB
,/,
due/JJ
to/TO
the/DT
limited/JJ
sample/NN
size/NN
,/,
some/DT
of/IN
the/DT
common/JJ
driver/RB
mutations/NNS
for/IN
CRCs/NNS
,/,
such/JJ
as/IN
RAS/NN
mutation/NN
,/,
were/VBD
unable/JJ
to/TO
be/VB
compared/VBN
./.
====================
Third/RB
,/,
the/DT
cancer/NN
panel/NN
was/VBD
not/RB
suitable/JJ
to/TO
analyze/VB
the/DT
CNAs/NNS
properly/RB
./.
====================
Therefore/RB
,/,
although/IN
the/DT
CNA/NN
profiles/NNS
were/VBD
largely/RB
consistent/JJ
between/IN
the/DT
primary/JJ
tumor/NN
and/CC
xenograft/NN
,/,
these/DT
data/NNS
are/VBP
not/RB
objective/VB
and/CC
solid/JJ
evidence/NN
to/TO
support/VB
the/DT
consistency/NN
of/IN
the/DT
CNA/NN
profiles/NNS
./.
====================
In/IN
conclusion/NN
,/,
we/PRP
performed/VBD
targeted/VBN
sequencing/NN
using/VBG
a/DT
custom/JJ
panel/NN
in/IN
both/CC
a/DT
primary/JJ
tumor/NN
and/CC
PDX/NN
tumor/NN
for/IN
colorectal/JJ
cancer/NN
./.
====================
We/PRP
identified/VBD
that/WDT
the/DT
PDX/NN
models/NNS
had/VBD
consistent/JJ
genetic/JJ
characteristics/NNS
,/,
including/VBG
key/JJ
driver/RB
genes/NNS
that/WDT
were/VBD
identified/VBN
in/IN
the/DT
primary/JJ
tumors/NNS
./.
====================
Our/PRP$
data/NNS
are/VBP
useful/JJ
evidence/NN
to/TO
support/VB
the/DT
application/NN
of/IN
PDX/NN
models/NNS
for/IN
precision/NN
medicine/NN
research/NN
and/CC
future/JJ
clinical/JJ
applications/NNS
./.
====================
Hematoxylin/NN
and/CC
eosin‒stained/JJ
sections/NNS
of/IN
three/CD
primary/JJ
colorectal/JJ
tumors/NNS
(/(
A/DT
,/,
C/NN
,/,
E/NN
)/)
and/CC
corresponding/JJ
xenograft/NN
tumors/NNS
(/(
B/NN
,/,
D/NN
,/,
F/NN
)/)
./.
====================
All/DT
of/IN
the/DT
patient-derived/JJ
xenografttumors/NNS
used/VBN
in/IN
this/DT
study/NN
were/VBD
passage-three/JJ
tissues/NNS
./.
====================
Somatic/JJ
mutations/NNS
identified/VBD
from/IN
the/DT
three/CD
primary/JJ
colorectal/JJ
cancers/NNS
and/CC
corresponding/JJ
patient-derived/JJ
xenograft/NN
tumors/NNS
./.
====================
(/(
A/NN
)/)
Comparison/NN
of/IN
somatic/JJ
mutations/NNS
between/IN
patient/NN
’/CD
s/NNS
primary/JJ
tumor/NN
(/(
human/JJ
)/)
and/CC
xenograft/NN
tumor/NN
(/(
xenograft/NN
)/)
./.
====================
Variant/JJ
allele/NN
frequencies/NNS
(/(
%/NN
)/)
and/CC
amino/NN
acid/NN
changes/NNS
are/VBP
indicated/VBN
in/IN
each/DT
colored/JJ
box/NN
./.
====================
CCA-1/NN
(/(
blue/JJ
)/)
,/,
CCA-2/NN
(/(
orange/NN
)/)
,/,
and/CC
CCA-3/NN
(/(
green/CD
)/)
./.
====================
(/(
B/NN
)/)
Respective/JJ
variant/JJ
allele/NN
frequencies/NNS
(/(
%/NN
)/)
between/IN
primary/JJ
(/(
human/JJ
)/)
and/CC
xenograft/NN
tumors/NNS
./.
====================
Copy/NN
number/NN
alterations/NNS
between/IN
primary/JJ
tumor/NN
(/(
A/NN
)/)
and/CC
corresponding/JJ
patient-derived/JJ
xenograft/NN
tumor/NN
(/(
B/NN
)/)
in/IN
CCA-1/NN
./.
====================
Red/VBN
arrows/VBZ
represent/VBP
RAF1/NN
amplification/NN
(/(
chromosome/NN
3p/NN
)/)
,/,
FGFR1/NN
amplification/NN
(/(
chromosome/NN
8p/NN
)/)
,/,
and/CC
MYC/NN
amplification/NN
(/(
chromosome/NN
8q/NN
)/)
,/,
respectively/RB
./.
====================
Non-silent/JJ
somatic/JJ
mutations/NNS
====================
Comparison/NN
of/IN
CN/NN
alterations/NNS
between/IN
primary/JJ
tumors/NNS
and/CC
xenograft/NN
tumors/NNS
====================
